

VEGFR2 siRNA (h): sc-29318

BACKGROUND

Three cell membrane receptor tyrosine kinases, Flt (also designated VEGF-R1), Flk-1 (also designated VEGF-R2) and Flt-4, putatively involved in the growth of endothelial cells, are characterized by the presence of seven immunoglobulin-like sequences in their extracellular domain. These receptors exhibit high degrees of sequence relatedness to each other as well as lesser degrees of relatedness to the class III receptors including CSF-1/Fms, PDGR, SLFR/Kit and Flt-3/Flk-2. Two members of this receptor class, Flt-1 and Flk-1, have been shown to represent high affinity receptors for vascular endothelial growth factors (VEGFs). On the basis of structural similarity to Flt and Flk-1, it has been speculated that Flt-4 might represent a third receptor for either VEGF or a VEGF-related ligand.

CHROMOSOMAL LOCATION

Genetic locus: KDR (human) mapping to 4q12.

PRODUCT

VEGFR2 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see VEGFR2 shRNA Plasmid (h): sc-29318-SH and VEGFR2 shRNA (h) Lentiviral Particles: sc-29318-V as alternate gene silencing products.

For independent verification of VEGFR2 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-29318A, sc-29318B and sc-29318C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

VEGFR2 siRNA (h) is recommended for the inhibition of VEGFR2 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

VEGFR2 (D-8): sc-393163 is recommended as a control antibody for monitoring of VEGFR2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor VEGFR2 gene expression knockdown using RT-PCR Primer: VEGFR2 (h)-PR: sc-29318-PR (20 μ l, 521 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

- Greenberg, J.I., et al. 2008. A role for VEGF as a negative regulator of pericyte function and vessel maturation. *Nature* 456: 809-813.
- Meissner, M., et al. 2009. Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells. *Cancer Res.* 69: 1976-1984.
- Funahashi, Y., et al. 2010. Notch regulates the angiogenic response via induction of VEGFR-1. *J. Angiogenes. Res.* 2: 3.
- Kang, D.H., et al. 2011. Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. *Mol. Cell* 44: 545-558.
- Dudgeon, C., et al. 2012. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3 β and NF κ B to suppress tumor cell growth. *Oncogene* 31: 4848-4858.
- Kohler, E.E., et al. 2014. Low-dose 6-bromoindirubin-3'-oxime induces partial dedifferentiation of endothelial cells to promote increased neovascularization. *Stem Cells* 32: 1538-1552.
- Goyal, A., et al. 2016. Endorepellin-evoked autophagy contributes to angiostasis. *J. Biol. Chem.* 291: 19245-19256.
- Rednam, C.K., et al. 2017. Increased survivability of ischemic skin flap tissue in Flk-1^{+/+} mice by Pellino-1 intervention. *Microcirculation*. E-published.
- Lee, C., et al. 2018. Dual targeting c-Met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. *Cancer Lett.* 414: 205-213.
- hao, H., et al. 2018. VEGF mitigates histone-induced pyroptosis in the remote liver injury associated with renal allograft ischemia-reperfusion injury in rats. *Am. J. Transplant.* 18: 1890-1903.
- Lamprou, M., et al. 2020. Pleiotrophin selectively binds to vascular endothelial growth factor receptor 2 and inhibits or stimulates cell migration depending on $\alpha_v\beta_3$ integrin expression. *Angiogenesis* 23: 621-636.

RESEARCH USE

For research use only, not for use in diagnostic procedures.